http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
-
Sema4 to Participate at Two Upcoming Investor Conferences in February
-
Sema4 to Participate at Two Upcoming Investor Conferences in February
-
Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities
-
Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities
-
Sema4 (SMFR) Acquires GeneDx from OPKO (OPK)
-
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
-
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
-
Sema4 (SMFR) Reports Prelim Q4 Revenue
-
Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021
-
Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021
-
Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January
-
Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January
-
Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights
-
Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights
-
Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction
-
Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction
-
Sema4 to Participate at Three Upcoming Investor Conferences in November
-
Sema4 to Participate at Three Upcoming Investor Conferences in November
-
Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
-
Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
-
Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer
-
Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health
-
Sema4 to Participate at Two Upcoming Investor Conferences in September
-
Sema4 to Participate at Two Upcoming Investor Conferences in September
-
Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights
-
Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights
-
Avera Health and Sema4 Announce Collaboration to Advance Precision Oncology Care
-
Sema4 to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
-
Sema4 to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
-
Sema4 to Participate at Two Upcoming Investor Conferences in August
-
Sema4 to Participate at Two Upcoming Investor Conferences in August
-
Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

